Commonwealth Equity Services, LLC Biocryst Pharmaceuticals Inc Transaction History

Commonwealth Equity Services, LLC

$66 Billion
Q3 2024

A detailed history of Commonwealth Equity Services, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 142,699 shares of BCRX stock, worth $1.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

142,699

Previous 143,874 0.82%

Holding current value

$1.11 Million

Previous $889,000 22.05%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$6.41 - $8.69 $7,531 - $10,210	-1,175 Reduced 0.82%	142,699 $1.09 Million
Q2 2024 Jul 31, 2024	SELL	$4.13 - $6.79 $5,988 - $9,845	-1,450 Reduced 1.0%	143,874 $889,000
Q1 2024 Apr 29, 2024	SELL	$4.89 - $7.65 $586 - $918	-120 Reduced 0.08%	145,324 $738,000
Q4 2023 Feb 06, 2024	SELL	$4.98 - $6.77 $82,867 - $112,652	-16,640 Reduced 10.27%	145,444 $871,000
Q2 2023 Aug 10, 2023	BUY	$6.96 - $8.81 $10,335 - $13,082	1,485 Added 0.92%	162,084 $1.14 Million
Q1 2023 May 11, 2023	BUY	$7.94 - $11.84 $46,846 - $69,856	5,900 Added 3.81%	160,599 $1.34 Million
Q4 2022 Feb 07, 2023	SELL	$10.5 - $14.2 $134,725 - $182,200	-12,831 Reduced 7.66%	154,699 $1.78 Million
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $1,834 - $2,517	170 Added 0.1%	167,530 $2.11 Million
Q2 2022 Jul 19, 2022	SELL	$7.89 - $17.88 $46,803 - $106,064	-5,932 Reduced 3.42%	167,360 $1.77 Million
Q1 2022 May 04, 2022	BUY	$11.56 - $19.76 $28,726 - $49,103	2,485 Added 1.45%	173,292 $2.82 Million
Q4 2021 Jan 31, 2022	BUY	$11.18 - $15.46 $565,529 - $782,028	50,584 Added 42.08%	170,807 $2.37 Million
Q3 2021 Oct 29, 2021	SELL	$14.21 - $17.65 $8,184 - $10,166	-576 Reduced 0.48%	120,223 $1.73 Million
Q2 2021 Aug 11, 2021	SELL	$9.5 - $17.24 $25,270 - $45,858	-2,660 Reduced 2.15%	120,799 $1.91 Million
Q1 2021 May 04, 2021	BUY	$7.37 - $13.61 $36,879 - $68,104	5,004 Added 4.22%	123,459 $1.26 Million
Q4 2020 Feb 11, 2021	SELL	$3.37 - $8.61 $4,856 - $12,407	-1,441 Reduced 1.2%	118,455 $882,000
Q3 2020 Nov 05, 2020	BUY	$3.43 - $5.53 $25,382 - $40,922	7,400 Added 6.58%	119,896 $411,000
Q2 2020 Aug 12, 2020	BUY	$1.9 - $5.61 $24,479 - $72,279	12,884 Added 12.93%	112,496 $536,000
Q1 2020 May 11, 2020	BUY	$1.6 - $4.11 $23,891 - $61,370	14,932 Added 17.63%	99,612 $199,000
Q4 2019 Feb 05, 2020	BUY	$1.59 - $3.45 $42,850 - $92,977	26,950 Added 46.68%	84,680 $292,000
Q3 2019 Oct 30, 2019	BUY	$2.5 - $3.73 $11,250 - $16,785	4,500 Added 8.45%	57,730 $165,000
Q2 2019 Jul 19, 2019	BUY	$2.91 - $9.15 $28,809 - $90,585	9,900 Added 22.85%	53,230 $201,000
Q2 2018 Jul 31, 2018	SELL	$4.6 - $6.52 $919 - $1,304	-200 Reduced 0.46%	43,330 $248,000
Q1 2018 May 14, 2018	BUY	$4.35 - $5.82 $2,610 - $3,492	600 Added 1.4%	43,530 $207,000
Q4 2017 Feb 12, 2018	BUY	$4.16 - $5.33 $178,588 - $228,816	42,930	42,930 $211,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.45B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.

Account

Commonwealth Equity Services, LLC Biocryst Pharmaceuticals Inc Transaction History